Gillette
This article was originally published in The Rose Sheet
Executive Summary
Massachusetts Secretary of the Commonwealth William Galvin issues subpoenas ad testificandum to several Gillette employees on May 11 to testify in connection with the state Securities Division's investigation of Procter & Gamble's acquisition of the razor manufacturer. Among those subpoenaed to testify later this month are Gillette CFO Charles Cramb, Board of Directors Vice Chairman Edward Degraan and Human Resources Manager Edward Guillet. Galvin has been investigating the merger since February, shortly after it was announced (1"The Rose Sheet" Feb. 7, 2005, p. 8). Gillette has resisted previous subpoenas issued by Galvin, recently requesting a Suffolk Superior Court quash a request for additional documents pertaining to the merger. The court ruled in favor of Gillette April 28 (2"The Rose Sheet" May 9, 2005, p. 7)...
You may also be interested in...
Gillette
Massachusetts Secretary of the Commonwealth William Galvin subpoena Gillette President & CEO James Kilts to testify June 1 regarding fairness opinions generated by Goldman, Sachs & Co. and UBS Securities in connection with the firm's acquisition by Procter & Gamble. Galvin also issues May 19 subpoenas al testificandum to Goldman Sachs employees Jack Levy and Stephan Feldgoise and UBS Securities' Richard Case and Blair Effron relating to fairness opinions provided by the firms. Galvin previously issued subpoenaes to Gillette employees in connection with the acquisition, which he has been investigating since February (1"The Rose Sheet" May 16, 2005, In Brief and 2"The Rose Sheet" Feb. 7, 2005, p. 8)...
New EU Approvals
The Pink Sheet's list of EU centralized approvals of new active substances has been updated to add two new products, including Ryzneuta, Evive Biotechnology's treatment for chemotherapy-induced neutropenia.
Pair Of Deaths Linked To Recalled Vyaire Medical Respiratory Devices
The US FDA has labelled a recall of more than 6 million Airlife respiratory support devices class I. The recall covers devices manufactured in 2017 or earlier that can fail to provide adequate ventilation.